| 12378230 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Mark E. Flanagan, Kentaro Futatsugi +8 more |
2025-08-05 |
|
| 12331041 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, Edward L. Conn, John M. Curto, Mark E. Flanagan +7 more |
2025-06-17 |
|
| 12319669 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, Mark E. Flanagan +9 more |
2025-06-03 |
|
| 12065434 |
Metabolites of GLP1R agonists |
Andrew John Bessire, David A. Griffith, Amit S. Kalgutkar, Timothy Frank Ryder |
2024-08-20 |
$1,045,292,000 |
| 11858916 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, Edward L. Conn, John M. Curto, Mark E. Flanagan +7 more |
2024-01-02 |
$249,725,000 |
| 11802121 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, Mark E. Flanagan +9 more |
2023-10-31 |
$284,263,000 |
| 11512070 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, Mark E. Flanagan +9 more |
2022-11-29 |
$2,104,375,000 |
| 11471458 |
Diacylglycerol acyl transferase 2 inhibitor |
Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Lee, Daniel J. Smaltz |
2022-10-18 |
$393,425,000 |
| 11065249 |
Diacylglycerol acyl transferase 2 inhibitor |
Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Lee, Daniel J. Smaltz |
2021-07-20 |
$421,669,000 |
| 10934279 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Mark E. Flanagan, Kentaro Futatsugi +8 more |
2021-03-02 |
$1,471,575,000 |
| 10851081 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, Mark E. Flanagan +9 more |
2020-12-01 |
$390,003,000 |
| 10683281 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Mark E. Flanagan, Kentaro Futatsugi +8 more |
2020-06-16 |
$1,092,312,000 |
| 10676465 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Mark E. Flanagan, Kentaro Futatsugi +8 more |
2020-06-09 |
$602,135,000 |
| 10669259 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, Mark E. Flanagan +9 more |
2020-06-02 |
$395,652,000 |
| 10208019 |
GLP-1 receptor agonists and uses thereof |
Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, Mark E. Flanagan +9 more |
2019-02-19 |
$915,842,000 |
| 9738626 |
Antagonists of prostaglandin EP3 receptor |
Kevin Bahnck, Daniel Canterbury, Kentaro Futatsugi, Esther Cheng Yin Lee, Elnaz Menhaji-Klotz +2 more |
2017-08-22 |
$672,498,000 |
| 9394285 |
Indole and indazole compounds that activate AMPK |
Samit Kumar Bhattacharya, Kimberly O. Cameron, Matthew S. Dowling, David Christopher Ebner, Dilinie Fernando +5 more |
2016-07-19 |
$914,444,000 |
| 9278953 |
Antagonists of prostaglandin EP3 receptor |
Kevin Bahnck, Kentaro Futatsugi, Esther Cheng Yin Lee, Alan M. Mathiowetz, Elnaz Menhaji-Klotz +1 more |
2016-03-08 |
$658,400,000 |
| 8802688 |
Substituted acetyl-coa carboxylase inhibitors |
Robert L. Dow, David A. Griffith, James Alfred Southers, JR. |
2014-08-12 |
$289,501,000 |
